期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis”
1
作者 Kenneth Blum Catherine A. Dennen +10 位作者 Eric R. Braverman Ashim Gupta David Baron Bernard William Downs Debasis Bagchi Panayotis Thanos maureen pollock Jag Khalsa Igor Elman Abdalla Bowirrat Rajendra D. Badgaiyan 《Open Journal of Immunology》 CAS 2022年第3期65-75,共11页
Pediatric autoimmune neuropsychiatric disorders associated with group A streptococcal infections (PANDAS) is a concept that is used to characterize a subset of children with neuropsychiatric symptoms, tic disorders, o... Pediatric autoimmune neuropsychiatric disorders associated with group A streptococcal infections (PANDAS) is a concept that is used to characterize a subset of children with neuropsychiatric symptoms, tic disorders, or obsessive-compulsive disorder (OCD), whose symptoms are exacerbated by group A streptococcal (GAS) infection. PANDAS has been known to cause a sudden onset of reward deficiency syndrome (RDS). RDS includes multiple disorders that are characterized by dopaminergic signaling dysfunction in the brain reward cascade (BRC), which may result in addiction, depression, avoidant behaviors, anxiety, tic disorders, and/or OCD. According to research by Blum et al., the dopamine receptor D2 (DRD2) gene polymorphisms are important prevalent genetic determinants of RDS. The literature demonstrates that infections like Borrelia and Lyme, as well as other infections like group A beta-hemolytic streptococcal (GABHS), can cause an autoimmune reaction and associated antibodies target dopaminergic loci in the mesolimbic region of the brain, which interferes with brain function and potentially causes RDS-like symptoms/behaviors. The treatment of PANDAS remains controversial, especially since there have been limited efficacy studies to date. We propose an innovative potential treatment for PANDAS based on previous clinical trials using a pro-dopamine regulator known as KB220 variants. Our ongoing research suggests that achieving “dopamine homeostasis” by precision-guided DNA testing and pro-dopamine modulation could result in improved therapeutic outcomes. 展开更多
关键词 PANDAS CANS Reward Deficiency Syndrome Group A Beta-Hemolytic Streptococcal (GABHS) Pro-Dopamine Regulation Dopamine Homeostasis Molecular Mimicry Lyme BORRELIA
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部